AbbVie Inc (ABBV)vsTalkspace Inc (TALK)
ABBV
AbbVie Inc
$248.67
-0.53%
HEALTHCARE · Cap: $430.82B
TALK
Talkspace Inc
$5.24
0.00%
HEALTHCARE · Cap: $872.74M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 26911% more annual revenue ($64.39B vs $238.37M). ABBV leads profitability with a 9.8% profit margin vs 0.5%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TALK
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.0%
Fair Value
$151.19
Current Price
$248.67
$97.48 premium
Intrinsic value data unavailable for TALK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Earnings expanding 181.1% YoY
Safe zone — low bankruptcy risk
18.2% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 1.0% — below average capital efficiency
0.5% margin — thin
Operating margin of 0.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : TALK
The strongest argument for TALK centers on EPS Growth, Altman Z-Score, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : TALK
The primary concerns for TALK are Market Cap, Return on Equity, Profit Margin. Thin 0.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while TALK is a growth play — different risk/reward profiles.
TALK carries more volatility with a beta of 1.07 — expect wider price swings.
TALK is growing revenue faster at 18.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 41/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Talkspace Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Talkspace Inc. is a virtual behavioral healthcare company. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?